Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
about
Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
P2860
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Assessing HER2 testing quality ...... bservational study in Germany.
@en
Assessing HER2 testing quality ...... bservational study in Germany.
@nl
type
label
Assessing HER2 testing quality ...... bservational study in Germany.
@en
Assessing HER2 testing quality ...... bservational study in Germany.
@nl
prefLabel
Assessing HER2 testing quality ...... bservational study in Germany.
@en
Assessing HER2 testing quality ...... bservational study in Germany.
@nl
P2093
P2860
P1433
P1476
Assessing HER2 testing quality ...... bservational study in Germany.
@en
P2093
Annette Lebeau
Claus Dieter Gerharz
Hans Kreipe
Johannes Ammann
Josef Rüschoff
Nicht-interventionelle Untersuchung (NIU) HER2 Study Group
Stefanie Morris
Winfried Koch
P2860
P2888
P304
P356
10.1038/MODPATHOL.2016.164
P577
2016-10-21T00:00:00Z